These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Pharmacologic profile of urapidil. Consequences for use as an antihypertensive drug]. van Zwieten PA Fortschr Med; 1992 Jun; 110(17):330-2. PubMed ID: 1353745 [TBL] [Abstract][Full Text] [Related]
4. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Thomas GN; Chan P; Tomlinson B Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636 [TBL] [Abstract][Full Text] [Related]
5. New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance. Cubeddu LX Am Heart J; 1988 Jul; 116(1 Pt 1):133-62. PubMed ID: 2899387 [TBL] [Abstract][Full Text] [Related]
6. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Gottdiener JS; Reda DJ; Massie BM; Materson BJ; Williams DW; Anderson RJ Circulation; 1997 Apr; 95(8):2007-14. PubMed ID: 9133508 [TBL] [Abstract][Full Text] [Related]
7. The role of alpha 1-blockers in combination therapy for hypertension. Zusman RM Int J Clin Pract; 2000; 54(1):36-40. PubMed ID: 10750258 [TBL] [Abstract][Full Text] [Related]
8. The cardiovascular effects of alpha-receptor blocking agents. Leren P J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110 [TBL] [Abstract][Full Text] [Related]
9. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. Hernández Hernández R; Angeli-Greaves M; Carvajal AR; Guerrero Pajuelo J; Armas Padilla MC; Armas-Hernández MJ Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174 [TBL] [Abstract][Full Text] [Related]
10. Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein. Kincaid-Smith P J Hum Hypertens; 1989 Dec; 3 Suppl 2():75-83. PubMed ID: 2575178 [TBL] [Abstract][Full Text] [Related]
11. [Alpha-receptor blocking agents and centrally acting antihypertensive agents]. de Leeuw PW Ned Tijdschr Geneeskd; 1988 Apr; 132(14):611-4. PubMed ID: 2896303 [No Abstract] [Full Text] [Related]
13. alpha 1-antagonists in the treatment of hypertension. Grimm RH Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457 [TBL] [Abstract][Full Text] [Related]
14. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Titmarsh S; Monk JP Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169 [TBL] [Abstract][Full Text] [Related]
15. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Itskovitz HD Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316 [TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction. Taylor SH Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744 [TBL] [Abstract][Full Text] [Related]
18. Role of α1-blockers in the current management of hypertension. Li H; Xu TY; Li Y; Chia YC; Buranakitjaroen P; Cheng HM; Van Huynh M; Sogunuru GP; Tay JC; Wang TD; Kario K; Wang JG J Clin Hypertens (Greenwich); 2022 Sep; 24(9):1180-1186. PubMed ID: 36196467 [TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Morgan T Clin Pharmacokinet; 1994 May; 26(5):335-46. PubMed ID: 7914479 [TBL] [Abstract][Full Text] [Related]
20. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. Hayduk K; Schneider HT Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]